QDEL logo

QuidelOrtho Corporation Stock Price

NasdaqGS:QDEL Community·US$2.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

QDEL Share Price Performance

US$29.98
-13.60 (-31.21%)
51.6% undervalued intrinsic discount
US$62.00
Fair Value
US$29.98
-13.60 (-31.21%)
50.0% undervalued intrinsic discount
US$60.00
Fair Value
Price US$29.98
AnalystHighTarget US$60.00
AnalystConsensusTarget US$40.33
AnalystLowTarget US$26.00

QDEL Community Narratives

AnalystHighTarget·Updated
Fair Value US$62 51.6% undervalued intrinsic discount

Expanding Access And Aging Demographics Will Redefine Diagnostics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$40.33 25.7% undervalued intrinsic discount

Global Expansion And Decentralized Testing Will Unlock Future Potential

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$26 15.3% overvalued intrinsic discount

Debt And Costs Will Squeeze Margins As Markets Rebound

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent QDEL News & Updates

QuidelOrtho Corporation Key Details

US$2.7b

Revenue

US$1.4b

Cost of Revenue

US$1.3b

Gross Profit

US$1.8b

Other Expenses

-US$466.4m

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-6.87
Gross Margin
47.29%
Net Profit Margin
-17.01%
Debt/Equity Ratio
93.5%

QuidelOrtho Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards

About QDEL

Founded
1979
Employees
6600
CEO
Brian Blaser
WebsiteView website
www.quidelortho.com

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.9%
  • 3 Months: 8.7%
  • 1 Year: 18.4%
  • Year to Date: 14.8%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 6.4%. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›